People Living With HIV Have More Intact HIV DNA in Circulating CD4+ T Cells if They Have History of Pulmonary Tuberculosis
Article Sidebar
Main Article Content
Abstract
Background: A primary barrier to curing HIV is the HIV reservoir. The leading infectious cause of death worldwide for people living with HIV is tuberculosis (TB), but we do not know how TB impacts the HIV reservoir.
Methods: Participants in identification and validation cohorts were selected from previously enrolled studies at Groupe Haïtien d’Étude du Sarcome de Kaposi et des Infections Opportunistes (GHESKIO) in Port au Prince, Haiti. Intact and non-intact proviral DNA were quantified using droplet digital PCR of peripheral blood mononuclear cell (PBMC)-derived CD4+ T cells.
Kruskal-Wallis tests were used to compare medians with tobit regression for censoring.
Results: In the identification cohort, we found that people living with HIV with a history of active pulmonary TB (n=19) had higher levels of intact provirus than people living with HIV without a history of active TB (n=47) (median 762; IQR, 183-1173 vs 117; IQR, 24-279 intact provirus per million CD4, respectively; P=0.0001). This difference also was seen in the validation cohort (n=31), (median 102; IQR, 0-737 vs 0; IQR, 0-24.5 intact provirus per million CD4, P=0.03) for TB vs no-TB history groups, respectively. The frequencies of CD4+ T cells with any detectable proviral fragment was directly proportional to the levels of interleukin-1 beta (r=0.524, P= 0.0025) and interleukin-2 (r=0.622, P=0.0002).
Conclusions: People living with HIV with a history of active pulmonary TB have more HIV provirus in their circulating CD4+ T cells, even years after TB cure. We need to characterize which CD4+ T cells are harboring intact provirus to consider the impact of T cell-targeting HIV cure interventions for people living in TB-endemic areas.
Downloads
Article Details
This work is licensed under a Creative Commons Attribution 4.0 International License.
Pathogens and Immunity abides by Creative Commons BY 4.0:
http://creativecommons.org/licenses/by/4.0/
This license lets others distribute, remix, tweak, and build upon your work for any lawful purpose, even commercially, as long as they credit you for the original creation. This is the most accommodating of licenses offered. Recommended for maximum dissemination and use of licensed materials. The authors maintain copyright of their materal.
*Due to a template error on our pdfs, articles published from May 20, 2016 to June 24, 2022 incorrectly state the copyright is held by Pathogens and Immunity. Copyright of all articles is held by the authors of each article as noted in the above copyright policy.
References
1. de Oliveira MF, Murrell B, Perez-Santiago J, Vargas M, Ellis RJ, Letendre S, Grant I, Smith DM, Woods SP, Gianella S. Circulating HIV DNA Correlates With Neurocognitive Impairment in Older HIV-infected Adults on Suppressive ART. Sci Rep. 2015;5:17094. doi: 10.1038/srep17094. PubMed PMID: 26603568; PMCID: PMC4658529.
2. Ruhanya V, Jacobs GB, Glashoff RH, Engelbrecht S. Clinical Relevance of Total HIV DNA in Peripheral Blood Mononuclear Cell Compartments as a Biomarker of HIV-Associated Neurocognitive Disorders (HAND). Viruses. 2017;9(11). doi: 10.3390/v9110324. PubMed PMID: 29088095; PMCID: PMC5707531.
3. Rouzioux C, Hubert JB, Burgard M, Deveau C, Goujard C, Bary M, Sereni D, Viard JP, Delfraissy JF, Meyer L, Group SCS. Early levels of HIV-1 DNA in peripheral blood mononuclear cells are predictive of disease progression independently of HIV-1 RNA levels and CD4+ T cell counts. J Infect Dis. 2005;192(1):46-55. doi: 10.1086/430610. PubMed PMID: 15942893.
4. Goujard C, Bonarek M, Meyer L, Bonnet F, Chaix ML, Deveau C, Sinet M, Galimand J, Delfraissy JF, Venet A, Rouzioux C, Morlat P, Agence Nationale de Recherche sur le Sida PSG. CD4 cell count and HIV DNA level are independent predictors of disease progression after primary HIV type 1 infection in untreated patients. Clin Infect Dis. 2006;42(5):709-15. doi: 10.1086/500213. PubMed PMID: 16447119.
5. Abrahams MR, Joseph SB, Garrett N, Tyers L, Moeser M, Archin N, Council OD, Matten D, Zhou S, Doolabh D, Anthony C, Goonetilleke N, Karim SA, Margolis DM, Pond SK, Williamson C, Swanstrom R. The replication-competent HIV-1 latent reservoir is primarily established near the time of therapy initiation. Sci Transl Med. 2019;11(513). doi: 10.1126/scitranslmed.aaw5589. PubMed PMID: 31597754; PMCID: PMC7233356.
6. Boulassel MR, Chomont N, Pai NP, Gilmore N, Sekaly RP, Routy JP. CD4 T cell nadir independently predicts the magnitude of the HIV reservoir after prolonged suppressive antiretroviral therapy. J Clin Virol. 2012;53(1):29-32. doi: 10.1016/j.jcv.2011.09.018. PubMed PMID: 22019250.
7. Massanella M, Bender Ignacio RA, Lama JR, Pagliuzza A, Dasgupta S, Alfaro R, Rios J, Ganoza C, Pinto-Santini D, Gilada T, Duerr A, Chomont N, Group MS. Long-term effects of early antiretroviral initiation on HIV reservoir markers: a longitudinal analysis of the MERLIN clinical study. Lancet Microbe. 2021;2(5):e198-e209. doi: 10.1016/S2666-5247(21)00010-0. PubMed PMID: 35544209.
8. Reddy K, Lee GQ, Reddy N, Chikowore TJB, Baisley K, Dong KL, Walker BD, Yu XG, Lichterfeld M, Ndung’u T. Differences in HIV-1 reservoir size, landscape characteristics and decay dynamics in acute and chronic treated HIV-1 Clade C infection. medRxiv. 2024. doi: 10.1101/2024.02.16.24302713. PubMed PMID: 38947072; PMCID: PMC11213047.
9. Stevenson EM, Terry S, Copertino D, Leyre L, Danesh A, Weiler J, Ward AR, Khadka P, McNeil E, Bernard K, Miller IG, Ellsworth GB, Johnston CD, Finkelsztein EJ, Zumbo P, Betel D, Dundar F, Duncan MC, Lapointe HR, Speckmaier S, Moran-Garcia N, Papa MP, Nicholes S, Stover CJ, Lynch RM, Caskey M, Gaebler C, Chun TW, Bosque A, Wilkin TJ, Lee GQ, Brumme ZL, Jones RB. SARS CoV-2 mRNA vaccination exposes latent HIV to Nef-specific CD8(+) Tcells. Nat Commun. 2022;13(1):4888. doi: 10.1038/s41467-022-32376-z. PubMed PMID: 35985993; PMCID: PMC9389512.
10. Jones RB, Kovacs C, Chun TW, Ostrowski MA. Short communication: HIV type 1 accumulates in influenza-specific T cells in subjects receiving seasonal vaccination in the context of effective antiretroviral therapy. AIDS Res Hum Retroviruses. 2012;28(12):1687-92. doi: 10.1089/AID.2012.0115. PubMed PMID: 22734882; PMCID: PMC3505056.
11. Gianella S, Anderson CM, Var SR, Oliveira MF, Lada SM, Vargas MV, Massanella M, Little SJ, Richman DD, Strain MC, Perez-Santiago J, Smith DM. Replication of Human Herpesviruses Is Associated with Higher HIV DNA Levels during Antiretroviral Therapy Started at Early Phases of HIV Infection. J Virol. 2016;90(8):3944-52. doi: 10.1128/JVI.02638-15. PubMed PMID: 26842469; PMCID: PMC4810527.
12. Gianella S, Tran SM, Morris S, Vargas M, Porrachia M, Oliveira MF, Lada S, Zhao M, Ellsworth GB, Mathad JS, Wilkin T. Sex Differences in CMV Replication and HIV Persistence During Suppressive ART. Open Forum Infect Dis. 2020;7(8):ofaa289. doi: 10.1093/ofid/ofaa289. PubMed PMID: 32793766; PMCID: PMC7415302.
13. Organization WH. WHO consolidated guidelines on tuberculosis 2024 [cited Module 6: Tuberculosis and comorbidities June 28, 2024]. Available from: https://iris.who.int/bitstream/handle/10665/376584/9789240087002-eng.pdf?sequence=1.
14. Olson A, Ragan EJ, Nakiyingi L, Lin N, Jacobson KR, Ellner JJ, Manabe YC, Sagar M. Brief Report: Pulmonary Tuberculosis Is Associated With Persistent Systemic Inflammation and Decreased HIV-1 Reservoir Markers in Coinfected Ugandans. J Acquir Immune Defic Syndr. 2018;79(3):407-11. doi: 10.1097/QAI.0000000000001823. PubMed PMID: 30063648; PMCID: PMC6506856.
15. Xun J, Qi T, Zou L, Tang Q, Shen Y, Yang J, Xie L, Ji Y, Zhang R, Liu L, Wang J, Steinhart C, Wang Z, Tang Y, Song W, Sun J, Cheng J, Le X, Wu H, He X, Chen R, Chen J, Lu H. Mycobacterium tuberculosis co-infection is associated with increased surrogate marker of the HIV reservoir. AIDS Res Ther. 2020;17(1):63. doi: 10.1186/s12981-020-00320-0. PubMed PMID: 33076959; PMCID: PMC7574250.
16. Goletti D, Weissman D, Jackson RW, Graham NM, Vlahov D, Klein RS, Munsiff SS, Ortona L, Cauda R, Fauci AS. Effect of Mycobacterium tuberculosis on HIV replication. Role of immune activation. J Immunol. 1996;157(3):1271-8. PubMed PMID: 8757635.
17. Toossi Z, Mayanja-Kizza H, Hirsch CS, Edmonds KL, Spahlinger T, Hom DL, Aung H, Mugyenyi P, Ellner JJ, Whalen CW. Impact of tuberculosis (TB) on HIV-1 activity in dually infected patients. Clin Exp Immunol. 2001;123(2):233-8. doi: 10.1046/j.1365-2249.2001.01401.x. PubMed PMID: 11207653; PMCID: PMC1905977.
18. Falcinelli SD, Ceriani C, Margolis DM, Archin NM. New Frontiers in Measuring and Characterizing the HIV Reservoir. Front Microbiol. 2019;10:2878. doi: 10.3389/fmicb.2019.02878. PubMed PMID: 31921056; PMCID: PMC6930150.
19. Bruner KM, Wang Z, Simonetti FR, Bender AM, Kwon KJ, Sengupta S, Fray EJ, Beg SA, Antar AAR, Jenike KM, Bertagnolli LN, Capoferri AA, Kufera JT, Timmons A, Nobles C, Gregg J, Wada N, Ho YC, Zhang H, Margolick JB, Blankson JN, Deeks SG, Bushman FD, Siliciano JD, Laird GM, Siliciano RF. A quantitative approach for measuring the reservoir of latent HIV-1 proviruses. Nature. 2019;566(7742):120-5. doi: 10.1038/s41586-019-0898-8. PubMed PMID: 30700913; PMCID: PMC6447073.
20. Simonetti FR, White JA, Tumiotto C, Ritter KD, Cai M, Gandhi RT, Deeks SG, Howell BJ, Montaner LJ, Blankson JN, Martin A, Laird GM, Siliciano RF, Mellors JW, Siliciano JD. Intact proviral DNA assay analysis of large cohorts of people with HIV provides a benchmark for the frequency and composition of persistent proviral DNA. Proc Natl Acad Sci U S A. 2020;117(31):18692-700. doi: 10.1073/pnas.2006816117. PubMed PMID: 32690683; PMCID: PMC7414172.
21. Kinloch NN, Ren Y, Conce Alberto WD, Dong W, Khadka P, Huang SH, Mota TM, Wilson A, Shahid A, Kirkby D, Harris M, Kovacs C, Benko E, Ostrowski MA, Del Rio Estrada PM, Wimpelberg A, Cannon C, Hardy WD, MacLaren L, Goldstein H, Brumme CJ, Lee GQ, Lynch RM, Brumme ZL, Jones RB. HIV-1 diversity considerations in the application of the Intact Proviral DNA Assay (IPDA). Nat Commun. 2021;12(1):165. doi: 10.1038/s41467-020-20442-3. PubMed PMID: 33420062; PMCID: PMC7794580.
22. Joseph Y, Yao Z, Dua A, Severe P, Collins SE, Bang H, Antoine Jean-Juste M, Ocheretina O, Apollon A, McNairy ML, Dupnik K, Cremieux E, Byrne A, Pape JW, Koenig SP. Long-term mortality after tuberculosis treatment among persons living with HIV in Haiti. J Int AIDS Soc. 2021;24(7):e25721. doi: 10.1002/jia2.25721. PubMed PMID: 34235862; PMCID: PMC8264404.
23. Organization WH. Haiti: HIV Country Profile 2023 2023 [June 28, 2024]. Available from: https://cfs.hivci.org/index.html.
24. Organization WH. Tuberculosis profile: Haiti.
25. Daniels JP. GHESKIO: adapting to challenges in Haiti since the early 1980s. Lancet HIV. 2019;6(3):e153. doi: 10.1016/S2352-3018(19)30048-7. PubMed PMID: 30846057.
26. Fitzgerald DW, Marotte C, Verdier RI, Johnson WD, Jr., Pape JW. Comprehension during informed consent in a less-developed country. Lancet. 2002;360(9342):1301-2. doi: 10.1016/S0140-6736(02)11338-9. PubMed PMID: 12414207.
27. Pape JW, Jean SS, Ho JL, Hafner A, Johnson WD, Jr. Effect of isoniazid prophylaxis on incidence of active tuberculosis and progression of HIV infection. Lancet. 1993;342(8866):268-72. doi: 10.1016/0140-6736(93)91817-6. PubMed PMID: 8101302.
28. Dupnik KM, Bean JM, Lee MH, Jean Juste MA, Skrabanek L, Rivera V, Vorkas CK, Pape JW, Fitzgerald DW, Glickman M. Blood transcriptomic markers of Mycobacterium tuberculosis load in sputum. Int J Tuberc Lung Dis. 2018;22(8):950-8. doi: 10.5588/ijtld.17.0855. PubMed PMID: 29991407; PMCID: PMC6343854.
29. Vorkas CK, Wipperman MF, Li K, Bean J, Bhattarai SK, Adamow M, Wong P, Aube J, Juste MAJ, Bucci V, Fitzgerald DW, Glickman MS. Mucosal-associated invariant and gammadelta T cell subsets respond to initial Mycobacterium tuberculosis infection. JCI Insight. 2018;3(19). doi: 10.1172/jci.insight.121899. PubMed PMID: 30282828; PMCID: PMC6237486.
30. Wipperman MF, Fitzgerald DW, Juste MAJ, Taur Y, Namasivayam S, Sher A, Bean JM, Bucci V, Glickman MS. Antibiotic treatment for Tuberculosis induces a profound dysbiosis of the microbiome that persists long after therapy is completed. Sci Rep. 2017;7(1):10767. doi: 10.1038/s41598-017-10346-6. PubMed PMID: 28883399; PMCID: PMC5589918.
31. Gunst JD, Pahus MH, Rosas-Umbert M, Lu IN, Benfield T, Nielsen H, Johansen IS, Mohey R, Ostergaard L, Klastrup V, Khan M, Schleimann MH, Olesen R, Stovring H, Denton PW, Kinloch NN, Copertino DC, Ward AR, Alberto WDC, Nielsen SD, Puertas MC, Ramos V, Reeves JD, Petropoulos CJ, Martinez-Picado J, Brumme ZL, Jones RB, Fox J, Tolstrup M, Nussenzweig MC, Caskey M, Fidler S, Sogaard OS. Early intervention with 3BNC117 and romidepsin at antiretroviral treatment initiation in people with HIV-1: a phase 1b/2a, randomized trial. Nat Med. 2022;28(11):2424-35. doi: 10.1038/s41591-022-02023-7. PubMed PMID: 36253609; PMCID: PMC10189540.
32. Holodniy M, Kim S, Katzenstein D, Konrad M, Groves E, Merigan TC. Inhibition of human immunodeficiency virus gene amplification by heparin. J Clin Microbiol. 1991;29(4):676-9. doi: 10.1128/jcm.29.4.676-679.1991. PubMed PMID: 1909709; PMCID: PMC269852.
33. Cillo AR, Vagratian D, Bedison MA, Anderson EM, Kearney MF, Fyne E, Koontz D, Coffin JM, Piatak M, Jr., Mellors JW. Improved single-copy assays for quantification of persistent HIV-1 viremia in patients on suppressive antiretroviral therapy. J Clin Microbiol. 2014;52(11):3944-51. doi: 10.1128/JCM.02060-14. PubMed PMID: 25187636; PMCID: PMC4313209.
34. McCann CD, van Dorp CH, Danesh A, Ward AR, Dilling TR, Mota TM, Zale E, Stevenson EM, Patel S, Brumme CJ, Dong W, Jones DS, Andresen TL, Walker BD, Brumme ZL, Bollard CM, Perelson AS, Irvine DJ, Jones RB. A participant-derived xenograft model of HIV enables long-term evaluation of autologous immunotherapies. J Exp Med. 2021;218(7). doi: 10.1084/jem.20201908. PubMed PMID: 33988715; PMCID: PMC8129803.
35. Tobin J. Estimation of Relationships for Limited Dependent Variables. Econometrica. 1958;26(1):24-36. doi: 10.2307/1907382. PubMed PMID: WOS:A1958CAL6600002.
36. Falcinelli SD, Shook-Sa BE, Dewey MG, Sridhar S, Read J, Kirchherr J, James KS, Allard B, Ghofrani S, Stuelke E, Baker C, Roan NR, Eron JJ, Kuruc JD, Ramirez C, Gay C, Mollan KR, Margolis DM, Adimora AA, Archin NM. Impact of Biological Sex on Immune Activation and Frequency of the Latent HIV Reservoir During Suppressive Antiretroviral Therapy. J Infect Dis. 2020;222(11):1843-52. doi: 10.1093/infdis/jiaa298. PubMed PMID: 32496542; PMCID: PMC7653086.
37. Prodger JL, Capoferri AA, Yu K, Lai J, Reynolds SJ, Kasule J, Kityamuweesi T, Buule P, Serwadda D, Kwon KJ, Schlusser K, Martens C, Scully E, Choi YH, Redd AD, Quinn TC. Reduced HIV-1 latent reservoir outgrowth and distinct immune correlates among women in Rakai, Uganda. JCI Insight. 2020;5(14). doi: 10.1172/jci.insight.139287. PubMed PMID: 32544096; PMCID: PMC7453892.
38. Severe P, Juste MA, Ambroise A, Eliacin L, Marchand C, Apollon S, Edwards A, Bang H, Nicotera J, Godfrey C, Gulick RM, Johnson WD, Jr., Pape JW, Fitzgerald DW. Early versus standard antiretroviral therapy for HIV-infected adults in Haiti. N Engl J Med. 2010;363(3):257-65. doi: 10.1056/NEJMoa0910370. PubMed PMID: 20647201; PMCID: PMC3676927.
39. Koenig SP, Dorvil N, Devieux JG, Hedt-Gauthier BL, Riviere C, Faustin M, Lavoile K, Perodin C, Apollon A, Duverger L, McNairy ML, Hennessey KA, Souroutzidis A, Cremieux PY, Severe P, Pape JW. Same-day HIV testing with initiation of antiretroviral therapy versus standard care for persons living with HIV: A randomized unblinded trial. PLoS Med. 2017;14(7):e1002357. doi: 10.1371/journal.pmed.1002357. PubMed PMID: 28742880; PMCID: PMC5526526.
40. Ahmed A, Vyakarnam A. Emerging patterns of regulatory T cell function in tuberculosis. Clin Exp Immunol. 2020;202(3):273-87. doi: 10.1111/cei.13488. PubMed PMID: 32639588; PMCID: PMC7670141.
41. Musvosvi M, Huang H, Wang C, Xia Q, Rozot V, Krishnan A, Acs P, Cheruku A, Obermoser G, Leslie A, Behar SM, Hanekom WA, Bilek N, Fisher M, Kaufmann SHE, Walzl G, Hatherill M, Davis MM, Scriba TJ, Adolescent Cohort Study t, Consortium GC. T cell receptor repertoires associated with control and disease progression following Mycobacterium tuberculosis infection. Nat Med. 2023;29(1):258-69. doi: 10.1038/s41591-022-02110-9. PubMed PMID: 36604540; PMCID: PMC9873565.
42. Gantner P, Buranapraditkun S, Pagliuzza A, Dufour C, Pardons M, Mitchell JL, Kroon E, Sacdalan C, Tulmethakaan N, Pinyakorn S, Robb ML, Phanuphak N, Ananworanich J, Hsu D, Vasan S, Trautmann L, Fromentin R, Chomont N. HIV rapidly targets a diverse pool of CD4(+) T cells to establish productive and latent infections. Immunity. 2023;56(3):653-68 e5. doi: 10.1016/j.immuni.2023.01.030. PubMed PMID: 36804957; PMCID: PMC10023508.
43. Mendoza P, Jackson JR, Oliveira TY, Gaebler C, Ramos V, Caskey M, Jankovic M, Nussenzweig MC, Cohn LB. Antigen-responsive CD4+ T cell clones contribute to the HIV-1 latent reservoir. J Exp Med. 2020;217(7). doi: 10.1084/jem.20200051. PubMed PMID: 32311008; PMCID: PMC7336300.
44. Geldmacher C, Ngwenyama N, Schuetz A, Petrovas C, Reither K, Heeregrave EJ, Casazza JP, Ambrozak DR, Louder M, Ampofo W, Pollakis G, Hill B, Sanga E, Saathoff E, Maboko L, Roederer M, Paxton WA, Hoelscher M, Koup RA. Preferential infection and depletion of Mycobacterium tuberculosis-specific CD4 T cells after HIV-1 infection. J Exp Med. 2010;207(13):2869-81. doi: 10.1084/jem.20100090. PubMed PMID: 21115690; PMCID: PMC3005236.
45. Waters R, Ndengane M, Abrahams MR, Diedrich CR, Wilkinson RJ, Coussens AK. The Mtb-HIV syndemic interaction: why treating M. tuberculosis infection may be crucial for HIV-1 eradication. Future Virol. 2020;15(2):101-25. doi: 10.2217/fvl-2019-0069. PubMed PMID: 32273900; PMCID: PMC7132588.
46. Scriba TJ, Penn-Nicholson A, Shankar S, Hraha T, Thompson EG, Sterling D, Nemes E, Darboe F, Suliman S, Amon LM, Mahomed H, Erasmus M, Whatney W, Johnson JL, Boom WH, Hatherill M, Valvo J, De Groote MA, Ochsner UA, Aderem A, Hanekom WA, Zak DE, other members of the ACScst. Sequential inflammatory processes define human progression from M. tuberculosis infection to tuberculosis disease. PLoS Pathog. 2017;13(11):e1006687. doi: 10.1371/journal.ppat.1006687. PubMed PMID: 29145483; PMCID: PMC5689825.
47. Gandhi RT, McMahon DK, Bosch RJ, Lalama CM, Cyktor JC, Macatangay BJ, Rinaldo CR, Riddler SA, Hogg E, Godfrey C, Collier AC, Eron JJ, Mellors JW, Team AA. Levels of HIV-1 persistence on antiretroviral therapy are not associated with markers of inflammation or activation. PLoS Pathog. 2017;13(4):e1006285. doi: 10.1371/journal.ppat.1006285. PubMed PMID: 28426825; PMCID: PMC5398724.
48. Pollack RA, Jones RB, Pertea M, Bruner KM, Martin AR, Thomas AS, Capoferri AA, Beg SA, Huang SH, Karandish S, Hao H, Halper-Stromberg E, Yong PC, Kovacs C, Benko E, Siliciano RF, Ho YC. Defective HIV-1 Proviruses Are Expressed and Can Be Recognized by Cytotoxic T Lymphocytes, which Shape the Proviral Landscape. Cell Host Microbe. 2017;21(4):494-506 e4. doi: 10.1016/j.chom.2017.03.008. PubMed PMID: 28407485; PMCID: PMC5433942.
49. Du Bruyn E, Fukutani KF, Rockwood N, Schutz C, Meintjes G, Arriaga MB, Cubillos-Angulo JM, Tiburcio R, Sher A, Riou C, Wilkinson KA, Andrade BB, Wilkinson RJ. Inflammatory profile of patients with tuberculosis with or without HIV-1 co-infection: a prospective cohort study and immunological network analysis. Lancet Microbe. 2021;2(8):e375-e85. doi: 10.1016/S2666-5247(21)00037-9. PubMed PMID: 35544195.
50. Kusejko K, Gunthard HF, Olson GS, Zens K, Darling K, Khanna N, Furrer H, Vetter P, Bernasconi E, Vernazza P, Hoffmann M, Kouyos RD, Nemeth J, Swiss HIVCS. Diagnosis of latent tuberculosis infection is associated with reduced HIV viral load and lower risk for opportunistic infections in people living with HIV. PLoS Biol. 2020;18(12):e3000963. doi: 10.1371/journal.pbio.3000963. PubMed PMID: 33284802; PMCID: PMC7721132.
51. Gupta A, Wood R, Kaplan R, Bekker LG, Lawn SD. Prevalent and incident tuberculosis are independent risk factors for mortality among patients accessing antiretroviral therapy in South Africa. PLoS One. 2013;8(2):e55824. doi: 10.1371/journal.pone.0055824. PubMed PMID: 23418463; PMCID: PMC3572168.
52. Riitho V, Connon R, Gwela A, Namusanje J, Nhema R, Siika A, Bwakura-Dangarembizi M, Musiime V, Berkley JA, Szubert AJ, Gibb DM, Walker AS, Klein N, Prendergast AJ. Biomarkers of mortality in adults and adolescents with advanced HIV in sub-Saharan Africa. Nat Commun. 2024;15(1):5492. doi: 10.1038/s41467-024-49317-7. PubMed PMID: 38944653; PMCID: PMC11214617.
53. Silverio D, Goncalves R, Appelberg R, Saraiva M. Advances on the Role and Applications of Interleukin-1 in Tuberculosis. mBio. 2021;12(6):e0313421. doi: 10.1128/mBio.03134-21. PubMed PMID: 34809460; PMCID: PMC8609357.
54. Xin H, Cao X, Zhang H, Liu J, Pan S, Li X, Guan L, Shen F, Liu Z, Wang D, Guan X, Yan J, Li H, Feng B, Zhang M, Yang Q, Jin Q, Gao L, Team L-NS. Dynamic changes of interferon gamma release assay results with latent tuberculosis infection treatment. Clin Microbiol Infect. 2020;26(11):1555 e1- e7. doi: 10.1016/j.cmi.2020.02.009. PubMed PMID: 32062048.
55. Rivera VR, Lu L, Ocheretina O, Jean Juste MA, Julma P, Archange D, Moise CG, Homeus F, Phanor PD, Petion S, Cremieux PY, Fitzgerald DW, Pape JW, Koenig SP. Diagnostic yield of active case finding for tuberculosis at human immunodeficiency virus testing in Haiti. Int J Tuberc Lung Dis. 2019;23(11):1217-22. doi: 10.5588/ijtld.18.0835. PubMed PMID: 31718759; PMCID: PMC7647668.